BioCentury
ARTICLE | Financial News

BridgeBio raises $299M to advance rare disease portfolio

January 25, 2019 12:26 AM UTC

BridgeBio Pharma LLC (Palo Alto, Calif.) said it raised $299.2 million on Jan. 23 in a venture round to develop compounds for rare genetic diseases.

The company in-licenses preclinical and clinical stage assets from academia and pharma, and houses them in individual subsidiaries. BridgeBio, which has disclosed 10 of its subsidiaries, raised a $135 million venture round in September (see "Orphan Opportunity")...